Newer area of the biotech space and one early mover is way out in front, Resverlogix with a drug named Apabetalone nearing the end of a Phase III event based trial for patients with Diabetes Mellitus as well as subsets of patients on dialysis (Chronic Kidney Disease) and reduced Cognitive function, (Alzheimer's).
This has blockbuster written all over it, but very the company is very quiet. No promoters or IR consultant types hyping it.
I guess they figure they don't need it. Here's a SA blog post I did.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.